Clorox Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
Clorox verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 7.4%, während die Gewinne der Branche Household Products jährlich um gewachsen und zwar um 1.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von rückläufig von 1.1%. Die Eigenkapitalrendite von Clorox beträgt 837% und die Nettomargen betragen 11.2%.
Wichtige Informationen
7.39%
Wachstumsrate der Gewinne
7.89%
EPS-Wachstumsrate
| Household Products Wachstum der Industrie | 1.51% |
| Wachstumsrate der Einnahmen | -1.08% |
| Eigenkapitalrendite | 836.96% |
| Netto-Marge | 11.18% |
| Letzte Ertragsaktualisierung | 31 Mar 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrativ-Update • May 14
CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings
Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.
Narrativ-Update • Apr 29
CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple
Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.Seeking Alpha • Apr 28
Clorox: Reduced Complexity Paves The Way For Multiple Expansion
Summary Clorox is attractively valued after underperformance, offering a 5% dividend yield and normalization post-cyber attack and ERP disruptions. The recent Purell (GOJO) acquisition is set to be accretive to EBITDA and EPS by FY27, supporting top-line growth above the company's long-term algorithm. CLX trades at 14.5x FY27 EPS, with double-digit earnings growth and room for multiple expansion relative to peers, setting up 20% upside potential. Risks include high customer concentration, private label competition, and consumer value-seeking behavior, but strong cash flow supports deleveraging and dividend sustainability. Read the full article on Seeking Alpha
Narrativ-Update • Apr 15
CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power
Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.Narrativ-Update • Mar 31
CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power
Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.Narrativ-Update • Mar 17
CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook
Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.Narrativ-Update • Mar 03
CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power
Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.Narrativ-Update • Feb 17
CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E
The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.Narrativ-Update • Feb 03
CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple
Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.Narrativ-Update • Jan 20
CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating
Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.Narrativ-Update • Jan 05
CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating
Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.Narrativ-Update • Dec 20
CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook
Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.Narrativ-Update • Dec 05
CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery
Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.Narrativ-Update • Nov 21
CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026
Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.Analyseartikel • Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet
Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...Analyseartikel • Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...Narrativ-Update • Nov 06
CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026
Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.Narrativ-Update • Oct 23
Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.Narrativ-Update • Oct 09
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.Narrativ-Update • Aug 27
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.Analyseartikel • Aug 04
Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24
The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...Analyseartikel • Aug 02
Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...Analyseartikel • Jul 16
Returns On Capital At Clorox (NYSE:CLX) Have Stalled
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Mar 29
Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking AlphaSeeking Alpha • Nov 26
The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals
Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking AlphaAufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Clorox Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 6,760 | 756 | 1,772 | 116 |
| 31 Dec 25 | 6,758 | 755 | 1,842 | 116 |
| 30 Sep 25 | 6,771 | 791 | 1,857 | 118 |
| 30 Jun 25 | 7,104 | 810 | 1,896 | 121 |
| 31 Mar 25 | 7,019 | 694 | 1,980 | 122 |
| 31 Dec 24 | 7,165 | 457 | 2,008 | 127 |
| 30 Sep 24 | 7,469 | 357 | 2,035 | 128 |
| 30 Jun 24 | 7,093 | 280 | 1,985 | 126 |
| 31 Mar 24 | 7,209 | 240 | 1,975 | 132 |
| 31 Dec 23 | 7,310 | 80 | 2,014 | 135 |
| 30 Sep 23 | 7,035 | 86 | 1,929 | 136 |
| 30 Jun 23 | 7,389 | 149 | 1,921 | 139 |
| 31 Mar 23 | 7,171 | 74 | 1,837 | 134 |
| 31 Dec 22 | 7,065 | 435 | 1,682 | 130 |
| 30 Sep 22 | 7,041 | 405 | 1,684 | 131 |
| 30 Jun 22 | 7,107 | 462 | 1,679 | 132 |
| 31 Mar 22 | 7,108 | 458 | 1,711 | 143 |
| 31 Dec 21 | 7,080 | 247 | 1,762 | 144 |
| 30 Sep 21 | 7,231 | 437 | 1,809 | 150 |
| 30 Jun 21 | 7,341 | 710 | 1,809 | 149 |
| 31 Mar 21 | 7,522 | 923 | 1,813 | 146 |
| 31 Dec 20 | 7,524 | 1,225 | 1,829 | 153 |
| 30 Sep 20 | 7,131 | 1,151 | 1,723 | 147 |
| 30 Jun 20 | 6,721 | 939 | 1,654 | 145 |
| 31 Mar 20 | 6,365 | 870 | 1,557 | 141 |
| 31 Dec 19 | 6,133 | 816 | 1,470 | 136 |
| 30 Sep 19 | 6,157 | 813 | 1,478 | 134 |
| 30 Jun 19 | 6,214 | 820 | 1,482 | 136 |
| 31 Mar 19 | 6,278 | 796 | 1,458 | 135 |
| 31 Dec 18 | 6,244 | 790 | 1,447 | 133 |
| 30 Sep 18 | 6,187 | 841 | 1,420 | 132 |
| 30 Jun 18 | 6,124 | 823 | 1,407 | 132 |
| 31 Mar 18 | 6,080 | 808 | 1,427 | 132 |
| 31 Dec 17 | 6,040 | 799 | 1,431 | 135 |
| 30 Sep 17 | 6,030 | 716 | 1,423 | 136 |
| 30 Jun 17 | 5,973 | 703 | 1,409 | 135 |
| 31 Mar 17 | 5,926 | 666 | 1,432 | 140 |
| 31 Dec 16 | 5,875 | 653 | 1,420 | 140 |
| 30 Sep 16 | 5,814 | 654 | 1,412 | 142 |
| 30 Jun 16 | 5,761 | 648 | 1,393 | 141 |
| 31 Mar 16 | 5,718 | 672 | 1,348 | 138 |
| 31 Dec 15 | 5,693 | 657 | 1,328 | 137 |
| 30 Sep 15 | 5,693 | 634 | 1,329 | 136 |
| 30 Jun 15 | 5,655 | 606 | 1,321 | 136 |
Qualität der Erträge: CLX hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: CLXDie aktuellen Gewinnspannen (11.2%) sind höher als im letzten Jahr (9.9%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: CLXIn den letzten 5 Jahren sind die Gewinne von 7.4% jährlich gestiegen.
Beschleunigtes Wachstum: CLXDas Gewinnwachstum des Unternehmens im letzten Jahr (8.9%) übertrifft seinen 5-Jahres-Durchschnitt (7.4% pro Jahr).
Erträge im Vergleich zur Industrie: CLX Das Gewinnwachstum im vergangenen Jahr (8.9%) übertraf nicht die Entwicklung der Branche Household Products 11.7% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: Die Eigenkapitalrendite von CLX(836.96%) ist zwar hervorragend, doch ist diese Kennzahl aufgrund der hohen Verschuldung des Unternehmens verzerrt.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/26 18:02 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
The Clorox Company wird von 34 Analysten beobachtet. 14 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Staszak | Argus Research Company |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |